Stoke Therapeutics, Inc. (STOK) Tops Q1 EPS by 5c

Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q1 EPS of ($0.57), $0.05 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $4.2 million versus the consensus estimate of $3.21 million.

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• LSI Industries (LYTS) Tops Q4 EPS by 3c, Beats on Revenue
• ScanSource (SCSC) Tops Q4 EPS by 32c